Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
www.pulmccm.org
Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments. In two randomized trials, reslizumab improved lung function and asthma symptoms in patients meeting these criteria. Patients without high eosinophil count in peripheral blood did not experience clinically meaningful effects on lung function and symptom control. The two manufacturer-funded phase III studies were published in CHEST. Eosinophils are important in the initiation and perpetuation of airway inflammation and airway remodeling. Asthma varies widely in its presentation and pathophysiology, but several asthma phenotypes are characterized by high eosinophil counts in the blood, sputum, and airways. CINQAIR acts by tightly binding the cytokine IL-5, preventing its activation of its receptor; this inhibition prevents activation of eosinophils and subsequent inflammation. In one of the studies, patients with poorly controlled asthma were randomized to receive intravenous reslizumab 3.0 mg/kg or placebo once every 4 weeks for 16 weeks. Patients were stratified and analyzed by baseline blood eosinophil count (<400 cells/μL or ≥400 cells/μL). The primary outcome was change in FEV1 from baseline to week 16. Secondary endpoints included asthma control scores, use of short-acting beta-agonists (SABAs) and forced vital capacity (FVC). A total of 492 patients received one or more doses of placebo (n=97) or reslizumab (n=395).
Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
Reslizumab (CINQAIR) worked as add-on…
Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments. In two randomized trials, reslizumab improved lung function and asthma symptoms in patients meeting these criteria. Patients without high eosinophil count in peripheral blood did not experience clinically meaningful effects on lung function and symptom control. The two manufacturer-funded phase III studies were published in CHEST. Eosinophils are important in the initiation and perpetuation of airway inflammation and airway remodeling. Asthma varies widely in its presentation and pathophysiology, but several asthma phenotypes are characterized by high eosinophil counts in the blood, sputum, and airways. CINQAIR acts by tightly binding the cytokine IL-5, preventing its activation of its receptor; this inhibition prevents activation of eosinophils and subsequent inflammation. In one of the studies, patients with poorly controlled asthma were randomized to receive intravenous reslizumab 3.0 mg/kg or placebo once every 4 weeks for 16 weeks. Patients were stratified and analyzed by baseline blood eosinophil count (<400 cells/μL or ≥400 cells/μL). The primary outcome was change in FEV1 from baseline to week 16. Secondary endpoints included asthma control scores, use of short-acting beta-agonists (SABAs) and forced vital capacity (FVC). A total of 492 patients received one or more doses of placebo (n=97) or reslizumab (n=395).